Factors for starting biosimilar TNF inhibitors in patients with rheumatic diseases in the real world.

MLA

Sung, Yoon-Kyoung, et al. “Factors for Starting Biosimilar TNF Inhibitors in Patients with Rheumatic Diseases in the Real World.” PloS One, vol. 15, no. 1, Jan. 2020, p. e0227960. EBSCOhost, https://doi.org/10.1371/journal.pone.0227960.

APA

Sung, Y.-K., Jung, S.-Y., Kim, H., Choi, S., Im, S. G., Lee, Y. S., Jang, E. J., & Cho, S.-K. (2020). Factors for starting biosimilar TNF inhibitors in patients with rheumatic diseases in the real world. PloS One, 15(1), e0227960. https://doi.org/10.1371/journal.pone.0227960

Chicago

Sung, Yoon-Kyoung, Sun-Young Jung, Hyoungyoung Kim, Seongmi Choi, Seul Gi Im, Yu Sang Lee, Eun Jin Jang, and Soo-Kyung Cho. 2020. “Factors for Starting Biosimilar TNF Inhibitors in Patients with Rheumatic Diseases in the Real World.” PloS One 15 (1): e0227960. doi:10.1371/journal.pone.0227960.